Navigation Links
Sinovac Reports Third Quarter 2008 Unaudited Financial Results
Date:11/18/2008

BEIJING, Nov. 18 /PRNewswire/ -- Sinovac Biotech Ltd. (Amex: SVA), a leading developer and provider of vaccines in China, today announced the Company's financial results for the three-month and nine-month periods ended September 30, 2008.

    Highlights
    -- Sales year-to-date increased 40% year-over-year to $34.1 million
    -- Operating income year-to-date rose 22.5% year-over-year to $12.4
       million
    -- Net income year-to-date maintained at same level year-over-year at $5.6
       million, inclusive of 25% income tax rate for 2008 versus 15% for 2007
    -- Cash and cash equivalents increased 9% to $20.5 million, compared to
       the second quarter of 2008, due to improved accounts receivable
       collection

Mr. Weidong Yin, Chairman, President and CEO, commented, "Our nine month sales growth was in line with our previously stated objective to increase sales by 35% to 45% over the prior year. As we continue to execute our business plan, management is very confident that the Company is on track to achieve the projected full year sales growth rate for 2008. At the same time, we have increased our investment in research and development in order to focus on long-term growth. The development of a vaccine against human enterovirus 71 (EV 71), which causes hand, foot, and mouth disease, is one of our R&D programs that demonstrate our strategy to develop novel vaccines. We expect this vaccine to become another top-selling flagship product similar to Healive(R), once it is developed and commercialized. Even though we are currently facing challenging financial markets, management continues to prudently execute its long-term growth strategy designed to maximize shareholder value."

Three Months Ended September 30, 2008

For the third quarter 2008, sales were $8.8 million,
'/>"/>

SOURCE Sinovac Biotech Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related biology technology :

1. Sinovac Named to Deloitte Technology Fast 50 China
2. Sinovac to Participate in Two Upcoming Investor Conferences
3. Sinovacs Credit Rating Upgraded to AAZ, Second Highest Rating
4. Sinovac Biotech Holds 2007 Annual General Meeting
5. Sinovac to Present at the 2008 UBS Global Life Sciences Conference
6. Sinovac Initiates Clinical Trials for Inactivated Hepatitis A Vaccine in Ukraine
7. Sinovac Launches Seasonal Influenza Vaccine Anflu(R) for 2008-2009 Flu Season
8. Sinovac Adjourns Annual General Meeting
9. Sinovac to Present at the Susquehanna Financial Groups Second Annual Beijing Management Summit Conference
10. Sinovac Reports Record Second Quarter 2008 Unaudited Financial Results
11. Sinovac Biotech Ltd. Schedules 2007 Annual Meeting of Shareholders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... DUBLIN, Ireland , September 18, ... ,Research and Markets ( http://www.researchandmarkets.com/research/czvg3s/biocompatible ) ... "Biocompatible Materials - Global Strategic ... offering. ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) ,This report ... Materials in US$ Million by the ...
(Date:9/18/2014)... On Tuesday, Secretary of Energy Ernest Moniz joined ... Lab Day on the Hill. The event highlighted several ... Durbin and Risch also formally launched the Senate National ... reach of the national labs as leaders in developing ... our nation's most pressing challenges. , "The national labs ...
(Date:9/18/2014)... Sept. 18, 2014 Research and ... "Global N-acetylcysteine Industry Report 2014" report ... N-acetylcysteine Industry Report 2014 is a professional and ... global N-acetylcysteine industry. The report provides ... classifications, applications and industry chain structure. The N-acetylcysteine ...
(Date:9/18/2014)... , Sept. 18, 2014 Research and ... "Global Companion Diagnostics (Polymerase Chain Reaction, In-situ hybridization, Immunohistochemistry) ... to their offering. The global companion ... of 22.7% from 2014 to 2019. Factors such as ... adoption of companion diagnostics by the pharmaceutical industry, support ...
Breaking Biology Technology:Biocompatible Materials - Global Strategic Business Report 2014 2Biocompatible Materials - Global Strategic Business Report 2014 3Lab Day Highlight Labs' Contribution to U.S. Competitiveness and Innovation 2Lab Day Highlight Labs' Contribution to U.S. Competitiveness and Innovation 3Global N-acetylcysteine Industry Report 2014 2Global Companion Diagnostics (Polymerase Chain Reaction, In-situ hybridization, Immunohistochemistry) Market - Trends & Forecasts to 2019 2Global Companion Diagnostics (Polymerase Chain Reaction, In-situ hybridization, Immunohistochemistry) Market - Trends & Forecasts to 2019 3
...   Sigma-Aldrich Corporation (NASDAQ: ... announced it has signed an agreement to acquire BioReliance Holdings, ... Avista Capital Partners for $350 million in cash.  The acquisition ... is expected to close in the first quarter of 2012.  ...
... According to a new market research report, ... , published by MarketsandMarkets ( http://www.marketsandmarkets.com ), global seed ... protection market. This growth is fueled by government encouragement ... This growth is particularly higher in geographies such as ...
... GENEVA, Jan. 9, 2012   Selexis SA announced ... Vice President of Strategic and Market Development. ... CEO, Dr. Igor Fisch and will be responsible for ... biologics and difficult-to-express protein markets. ...
Cached Biology Technology:Sigma-Aldrich to Acquire BioReliance; Extending Its Reach into Biopharmaceutical Testing and Services 2Sigma-Aldrich to Acquire BioReliance; Extending Its Reach into Biopharmaceutical Testing and Services 3Sigma-Aldrich to Acquire BioReliance; Extending Its Reach into Biopharmaceutical Testing and Services 4MarketsandMarkets: Global Seed Treatment Market worth $3430.3 Million by 2016 2MarketsandMarkets: Global Seed Treatment Market worth $3430.3 Million by 2016 3Selexis SA Appoints Yemi Onakunle as Vice President of Strategic and Market Development 2
(Date:9/17/2014)... health care to reproductive technologies, the justice and ... of people to identify key issues, articulate their ... find the most defensible ways forward. But what ... societal conversations?, The Hastings Center and the Presidential ... teamed up to publish a series of essays ...
(Date:9/17/2014)... Fauna Europaea started in 2000 as an EC-FP5 four-year ... years of steady progress and successful participations in several ... European Biodiversity Observation Network project (EU BON), to ... the contributors and to extend the general dissemination of ... Journal has applied its novel e-Publishing tools ...
(Date:9/17/2014)... research from the Copenhagen Centre for Social Evolution and ... theory that birth weight and -length can partially predict ... such as autism and schizophrenia later in life. The ... and subsequent hospital diagnoses for up to 30 years, ... The study is published today in the Proceedings ...
Breaking Biology News(10 mins):Why bioethics literacy matters 2Why bioethics literacy matters 3Contributions on Fauna Europaea: Data papers as innovative model on expert involvement 2Size at birth affects risk of adolescent mental health disorders 2Size at birth affects risk of adolescent mental health disorders 3
... transcription the process inside the nucleus of cells by ... a large, ever-changing multiprotein complex is enlisted to assist ... an exquisitely choreographed dance, each step in the process has ... to be accurate and useful in subsequent events. These ...
... discovery by Canada-U.S. biophysicists will improve the understanding of ion ... which when they malfunction can cause genetic illnesses that attack ... As reported in the current issue of the Proceedings ... researchers from the Universit de Montral and the University of ...
... we maximise the value and use of epidemiological ... the theme of a conference being held on ... Co-organised by PHOEBE (Promoting Harmonisation of Epidemiological Biobanks), ... (Biobanking and Biomolecular Resources Research Infrastructure), the conference ...
Cached Biology News:CSHL scientists discover new way in which ubiquitin modifies transcriptional machinery 2Researchers advance knowledge of little 'nano-machines' in our body 2Harmonizing Biobank Research Conference in 2009 2Harmonizing Biobank Research Conference in 2009 3
... vaccinia virus is a type I eukaryotic ... superhelical turns (also called right- and left-handed ... of the reaction is a covalently closed, ... superhelical turns. DNA Topoisomerase I does not ...
Applications include ELISA, immunochemistry, and Western blotting. Working Concentrations: ELISA: 0.005-0.05 U/ml, immunohisto/cytochemistry: 0.25-0.5 U/ml, Western blot: 0.1-0.25 U/ml....
...
Recombinant Ovine IFN Tau. Active on sheep, cow, human and mouse cells. Activity: 5.7 x 10 7 u/mg...
Biology Products: